Merck & Company Inc

Pfizer's decade-long streak of annual dividend increases has stalled, with its quarterly payout holding at $0.43 through the September 1, 2026 payment after the January 2026 ex-dividend date matched the prior four quarters instead of rising. The 6.20% yield remains covered by reaffirmed 2026 adjusted diluted EPS guidance of $2.80 to $3.00 against a run-rate $1.72 annual payout, and Q1 2026 adjusted EPS of $0.75 beat consensus for a fifth consecutive quarter above estimates. Cash outflow is real, with $2.4 billion in dividends paid in Q1 alone and $9.8 billion for full-year 2025, while Pfizer completed no buybacks in 2025 and anticipates none in 2026 despite $3.3 billion of unused authorization. On the August 4, 2026 call, incoming interim CFO Cecile Guegan said Pfizer would keep maintaining and over the long term growing the dividend, and Chairman and CEO Albert Bourla said the dividend will be maintained and eventually start growing again after the loss-of-exclusivity period. Peers have not frozen their payouts: Merck raised its quarterly from $0.81 to $0.85 starting with the December 2025 ex-date, and Bristol-Myers Squibb nudged its payout from $0.62 to $0.63 with the January 2026 ex-date. The pressure behind the pause is visible in the mix, with Comirnaty down 59% and Paxlovid down 62% in Q1 2026 and roughly $1.5 billion in additional generic and biosimilar headwind guided for the year, partly offset by launched and acquired products growing 22% operationally and Vyndamax exclusivity now running to June 2031.

Merck announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of KEYTRUDA, the company's anti-PD-1 therapy, in combination with Padcev as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invasive bladder cancer. The recommendation, which also includes KEYTRUDA SC, known as KEYTRUDA QLEX in the U.S., will now be reviewed by the European Commission for marketing authorization in the European Union, Iceland, Liechtenstein and Norway, with a final decision expected by the fourth quarter of 2026. The opinion is based on results from the Phase 3 KEYNOTE-B15 trial, also known as EV-304, conducted in collaboration with Pfizer and Astellas, in which the perioperative regimen reduced the risk of event-free survival events by 47% (HR=0.53) and the risk of death by 35% (HR=0.65) versus neoadjuvant chemotherapy and surgery in cisplatin-eligible patients, while pathologic complete response reached 55.8% versus 32.5%. If approved, KEYTRUDA plus Padcev would become the first and only PD-1 inhibitor plus antibody-drug conjugate regimen in the European Union for patients with MIBC regardless of cisplatin eligibility. In June 2026, the European Commission approved the combination for cisplatin-ineligible adults with resectable MIBC based on the Phase 3 KEYNOTE-905 trial, and in July 2026 the U.S. Food and Drug Administration approved it for adults with MIBC regardless of cisplatin eligibility based on KEYNOTE-B15.

Merck shares rose approximately 1.0% to $146.39 Thursday as the pharmaceutical and oncology heavyweight entered the next era of commercial space research, with its blockbuster cancer drug Keytruda already benefiting from work conducted in orbit. Research aboard the International Space Station helped scientists better understand protein crystallization, contributing to the development of a faster subcutaneous formulation of Keytruda, and NASA's research overview explains that microgravity can produce larger and more orderly protein crystals, potentially giving researchers clearer structural information. As the ISS approaches retirement, commercial stations could offer drugmakers dedicated equipment and more predictable research schedules, although regulators still lack a purpose-built approval framework for medicines manufactured in space. The commercial stakes are already enormous: Keytruda generated about $8.37 billion of Merck's latest $16.61 billion quarter, roughly half of total revenue, while the subcutaneous version contributed $463 million, or around 5.5% of Keytruda sales. At $146.39, Merck trades 21.85% above its GF Value estimate of $120.14, signaling that investors are already paying a meaningful premium to the model's estimate of fair value.

Moderna and Merck reported positive results from the late-stage INTerpath-001 study of intismeran autogene (V940/mRNA-4157) in combination with Keytruda in patients with high-risk Stage IIB-IV melanoma whose tumors had been removed through surgery. The study met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, with the companies stating the improvements were statistically significant and clinically meaningful, though no numerical data were disclosed. INTerpath-001 marks the first positive phase III readout for an individualized neoantigen therapy and an mRNA-based cancer therapy, and five-year follow-up from the phase IIb KEYNOTE-942 study showed the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% versus Keytruda alone. Moderna and Merck are evaluating intismeran across nine phase II and phase III studies spanning multiple tumor types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma, while Moderna's broader pipeline includes separate mRNA-based cancer antigen therapies, a T-cell engager and a cell-therapy enhancer. Moderna shares have skyrocketed nearly 400% year to date, outperforming the industry's 7% growth, and the stock trades at 23.44 times forward 12-month sales versus the industry average of 1.90 times.

Immunocore announced it has reached target enrollment of 540 patients in the phase III TEBE-AM study, which is evaluating its sole marketed drug, Kimmtrak, in patients with second-line or later advanced melanoma. The randomized, registrational trial is testing Kimmtrak as a monotherapy and in combination with Merck's PD-L1 inhibitor Keytruda versus investigator's choice in HLA-A*02:01-positive patients whose disease progressed after prior therapy, with overall survival as the primary endpoint. Immunocore expects to report top-line overall survival data from TEBE-AM as early as the end of 2026, and management says Kimmtrak could address a significant unmet need among up to 4,000 HLA-A*02:01-positive patients with previously treated advanced melanoma in the post-PD1 setting. Kimmtrak is currently approved for unresectable or metastatic uveal melanoma, and its sales rose 16% year over year to $222.6 million in the first half of 2026. Merck recorded $16.40 billion in Keytruda sales in the first half of 2026, up 4.2% year over year.

Perspective Therapeutics has signed a clinical trial collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda, Merck's anti-PD-1 therapy, in patients with FAP-α-positive solid tumors. The combination will be tested under an amendment to Perspective's ongoing Phase 1/2a study of [212Pb]PSV359 in certain types of non-small cell lung cancer and colorectal cancer that express fibroblast activation protein alpha, under clinicaltrials.gov identifier NCT06710756. Perspective is sponsoring the study and Merck is providing pembrolizumab at no cost, with enrollment already completed in the first three monotherapy dose cohorts. Markus Puhlmann, Perspective's Chief Medical Officer, said FAP-α is associated with the majority of solid tumors and a tumor microenvironment historically characterized by poor drug penetration and immune suppression or exclusion, and that combining targeted radiopharmaceutical treatment with a well-established immune checkpoint inhibitor may reshape the tumor environment and improve outcomes for patients with advanced FAP-α-positive solid tumors.

Merck & Co. reported second-quarter worldwide sales of $16.6 billion, with its oncology franchise led by intravenous Keytruda and the subcutaneous formulation Keytruda QLEX generating $8.4 billion in quarterly revenue. The pulmonary arterial hypertension treatment Winrevair surged 75% to reach $588 million, and management raised its full-year 2026 sales guidance to a range between $66.3 billion and $67.3 billion. The company faces the loss of exclusivity for Keytruda toward the end of 2028, pushing it to fund and acquire new pipeline assets, including a personalized mRNA cancer vaccine collaboration with Moderna. According to Insider Monkey's database, 101 hedge funds held a stake in the company during the second quarter, up from 98 in the prior quarter, while short interest sits at just 0.99% of the float. Fisher Asset Management maintained the top position with 38.5 million shares, increasing its holdings by 46%.

Merck is relying on a growing pipeline and an expanding portfolio of newer medicines, including acquired assets, to offset the eventual loss of exclusivity for its blockbuster cancer drug Keytruda. Keytruda generated sales of $16.40 billion in the first half of 2026, up nearly 4.2% year over year, and is expected to remain strong until it loses patent exclusivity in 2028, after which biosimilars entering around 2028-2029 are likely to drive a sharp decline. Merck's phase III pipeline has almost tripled since 2021, and the company expects to launch 20 new drugs by 2030, with newer products already emerging as growth drivers: pulmonary arterial hypertension drug Winrevair and 21-valent pneumococcal conjugate vaccine Capvaxive generated $1.1 billion and $325 million, respectively, in first-half 2026 sales, while cancer drug Welireg sales surged 57% year over year to $470 million. Merck expects more than $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s, more than double the peak consensus sales estimate for Keytruda of $35 billion in 2028, and has stepped up acquisitions ahead of the patent expiry with deals for Verona Pharma, Cidara Therapeutics and Terns Pharmaceuticals. Management expects the Keytruda LOE period to look like a shallow dip with a fast return back to growth, even as Keytruda faces competition from Bristol Myers' Opdivo, Roche's Tecentriq and AstraZeneca's Imfinzi.

The government is pressing ahead with negotiations with 10 global pharmaceutical companies to attract clinical research investment, manufacturing technology transfer, and workforce development into Thailand under a strategy to position the country as a Medical Investment Hub. Lalida Periswiwatana, deputy spokesperson for the Prime Minister's Office, said on September 11, 2026, that the approach falls under the Joint Public-Private Committee for Solving Economic Problems, known as the Kor Or, chaired by Prime Minister Anutin Charnvirakul, and the subcommittee on developing new national investment, chaired by Deputy Prime Minister and Finance Minister Ekniti Nitithanprapas. The government is applying an Offset Policy concept in talks with foreign companies so that government procurement extends into domestic investment. The Ministry of Public Health, under Minister Phatana Promphat, is negotiating with all 10 drugmakers, with the Board of Investment joining in considering investment promotion measures. Cooperation with MSD is the first Quick Win to show concrete results, with one new drug research program carrying an investment value of about 2 billion baht and the potential to create roughly 1,000 jobs. There are also plans to extend cooperation on technology transfer and the production of active pharmaceutical ingredients, or APIs, for a new HIV drug together with the Government Pharmaceutical Organization. Lalida said that within about two weeks the government plans to sign an additional cooperation agreement with Sandoz to draw global companies into investing and generating economic activity in Thailand, rather than having the public sector simply buy products from abroad.

Moderna's stock surged as much as 160% after the company announced positive Phase 3 trial results for its mRNA-based personalized cancer vaccine, which significantly reduced the risk of melanoma recurrence in over 1,100 patients when combined with Merck's Keytruda. The trial was stopped early because the efficacy was so high that standard medical ethics required allowing control-group patients access to the treatment. Despite the jump, shares remain below previous highs, and analysts caution that scaling and pricing questions remain. Meanwhile, Target reported a 5.3% sales increase and a 100% jump in earnings per share, though much of that came from a one-time $994 million tariff refund. The company's digital sales grew 8.7%, and same-day deliveries rose 25%, but analysts question whether the turnaround can sustain the stock's 60% year-to-date gain. In AI news, OpenAI's 18% quarterly growth disappointed investors, while Anthropic more than doubled revenue, and both companies are racing toward IPOs.

DelveInsight projects the ulcerative colitis market across the seven major markets—the US, EU4, UK, and Japan—will grow from approximately USD 9.4 billion in 2025 at a CAGR of 7.6% through 2036, driven by novel targeted therapies and a robust pipeline of late-stage candidates. Among these, Abivax's obefazimod, a first-in-class oral miR-124 enhancer, met its primary endpoint in Phase III ABTECT induction studies, with a pooled placebo-adjusted clinical remission rate of 16.4% at Week 8. Merck's tulisokibart, acquired via Prometheus Biosciences, achieved clinical remission in the Phase 3 ATLAS-UC study, while Roche's afimkibart, from its $7.1 billion Telavant acquisition, showed a 35% remission rate in Phase IIb TUSCANY-2. Johnson & Johnson and Protagonist Therapeutics' icotrokinra, a first-in-class oral IL-23 receptor antagonist, met its primary endpoint in the Phase 2b ANTHEM-UC trial, and Teva and Sanofi's duvakitug, backed by a $400 million Blackstone funding deal, is in Phase III. These therapies target unmet needs in moderate-to-severe disease, with the market shifting toward IL-23 inhibitors and oral advanced therapies, though biosimilars and established anti-TNFs remain widely used.

Gilead Sciences has received FDA approval for Bixlenvo, the smallest once-daily single-tablet regimen for HIV in virologically suppressed adults, making it the first and only option for patients unable to take existing single-tablet regimens. The drug combines bictegravir and lenacapavir, offering a high barrier to resistance and no cross-resistance to current antiretrovirals. This approval strengthens Gilead's HIV portfolio, which already includes Biktarvy, Descovy, and the rapidly growing Yeztugo, and the company has raised its 2026 HIV sales growth outlook to 9-10%, supported by a roughly $4 billion annualized PrEP business. Gilead expects Yeztugo sales to approach $1 billion in 2026, and its pipeline, including a once-weekly oral combination with Merck, offers additional upside. Shares of Gilead have gained 20.3% year to date, and the company currently holds a Zacks Rank #1 (Strong Buy).

DelveInsight reports that the PCSK9 inhibitors market is entering a high-growth phase, driven by the FDA approval of Merck's LIPFENDRA, the first oral PCSK9 inhibitor, and the emergence of next-generation oral drugs from AstraZeneca, Aqur Biosciences, and others. The market was valued at USD 3 billion in the 7MM in 2025, with the United States holding the largest share. Key pipeline candidates include Recaticimab, VERVE 102, AZD0780, AQR-008, and LIB003, with LEQVIO expected to generate the highest revenue by 2036. The report covers indications such as dyslipidemia, hypercholesterolemia, ASCVD, and others, and highlights that oral and gene therapies offer significant potential to reduce patient burden and improve adherence.

Merck and Moderna announced a significant breakthrough in melanoma treatment, as their jointly developed mRNA cancer vaccine met the primary goal in its first Phase 3 trial, significantly extending the period patients lived without melanoma recurrence when combined with Merck's Keytruda compared to Keytruda alone. Following the announcement on Aug. 19, Moderna's shares surged nearly 177%, while Merck rose 12.60%. The global melanoma therapeutics market, estimated at $5.83 billion in 2024, is projected to reach $10.27 billion by 2030, with immunotherapy as the fastest-growing segment. Barclays analysts estimate the vaccine could generate up to $3 billion in annual melanoma-related sales by 2035. Investors seeking exposure may consider healthcare ETFs holding these stocks, such as the iShares Genomics Immunology and Healthcare ETF, where Moderna holds an 8.85% weight, and the VanEck Pharmaceutical ETF, where Merck holds a 10.94% weight.

Moderna led the S&P 500 in August after reporting promising results from a late-stage trial of a personalized mRNA cancer vaccine co-developed with Merck, according to CNBC. The data challenged years of skepticism about the company's mRNA technology following the decline of its Covid-19 vaccine business. Enterprise software stocks accounted for many of the index's other top performers, including Palantir, Veeva Systems, Salesforce, and ServiceNow, which had been under selling pressure due to AI concerns and large short positions held by the leveraged hedge fund Situational Awareness. When the fund was forced to unwind its trades in late July, those shorts became a tailwind for the stocks. Situational Awareness, run by Leopold Aschenbrenner, peaked at $45 billion in assets and lost roughly $35 billion after margin calls from prime brokers Bank of America, Goldman Sachs, and JPMorgan Chase forced a distressed sale to Ken Griffin's Citadel. Salesforce bounced back after better-than-expected quarterly results, while ServiceNow gained on AI integration, and Veeva Systems climbed as the anticipated AI threat failed to materialize. Outside software, Newmont benefited from gold price recovery, Coinbase rose with cryptocurrencies, and Super Micro Computer and Sandisk surged on AI memory demand. Moderna also raised $2 billion through convertible senior notes due 2032, earmarked for its cancer vaccine business, after its stock surged 177% on Aug. 19, adding $44.5 billion to its market capitalization in a single session.

Moderna Inc. saw its share price soar 156 percent in August, making it the highest-gaining stock for the month, driven primarily by strong clinical trial results for its melanoma therapy candidate and supported by a recent regulatory approval for its updated COVID-19 vaccines. The company, in partnership with Merck, is developing a treatment for melanoma combining mRNA-4157 with Keytruda; the phase 3 trial met its primary endpoint of recurrence-free survival and the key secondary target of distant metastasis-free survival, marking the first positive readout from a phase 3 trial for a combination of individualized neoantigen therapy and mRNA-based cancer therapy, and the first to show a clinically meaningful improvement over Keytruda alone. The US alone is expected to see 112,000 new melanoma cases this year, with 8,500 deaths, and globally 330,000 cases were diagnosed in 2022. The rally was also supported by the FDA's approval of Moderna's biologics license application for the 2026-2027 formulas of Spikevax and mNEXSPIKE vaccines, with Spikevax approved for individuals aged 6 months to 64 with at least one underlying condition and all adults 65 and older, and mNEXSPIKE approved for those 12 to 64 with high-risk conditions and all adults 65 and older. Hedge fund conviction strengthened in the second quarter, with 49 funds holding positions, down from 52, but their combined holdings increased 10 percent to $1.5 billion from $1.4 billion quarter-on-quarter.

Merck and Moderna have announced the first positive Phase 3 results for an individualized mRNA neoantigen cancer therapy in melanoma patients, tested in combination with Merck's immunotherapy KEYTRUDA. This marks the first time an mRNA-based personalized neoantigen approach has shown clinically meaningful and statistically significant Phase 3 data in cancer, signaling a potential new path for personalized cancer vaccines. The Phase 3 INTerpath-001 trial covers stage IIB to IV melanoma after surgery, a high-risk group where patients already receive KEYTRUDA in many markets. If regulators approve the combination, Merck could deepen its reach in this existing franchise and add a personalized mRNA revenue stream. The positive readout supports Merck's strategy to offset future KEYTRUDA exclusivity risk with new growth drivers, as its pipeline has nearly tripled since 2021. Investors should watch regulatory filings, overall survival data, and timelines for the other eight INTerpath trials across lung, bladder, and renal cancers.

The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in late June. The spark was a single piece of clinical trial news: Moderna and Merck announced on August 19 that their tailored mRNA cancer treatment was successful in a late-stage trial, significantly improving recurrence-free survival and distant metastasis-free survival compared with Keytruda alone in a study of over 1,100 patients. The Phase 3 trial, dubbed INTerpath-001, tested an individualized cancer vaccine called intismeran autogene in combination with Merck's blockbuster immunotherapy Keytruda in patients with completely resected stage IIB-IV melanoma. The trial achieved both its primary goals, recurrence-free survival, and a critical secondary target, distant metastasis-free survival, when compared to Keytruda alone. The companies stated that no new safety signals arose throughout the trial, and that the results expanded on previous Phase 2b data showing that the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared to Keytruda alone. Personalized neoantigen vaccines have been considered as a cancer treatment concept for many years, but this is the first randomized Phase 3 experiment to definitely confirm their effectiveness. Moderna shares rose around 177% on the day of the news, adding approximately $45 billion to the company's market capitalization, while Merck posted a more modest but still significant 12% single-day rise. More broadly, roughly two-thirds of health-care stocks in a broad screen of over 100 names were higher on the week, with pharmaceutical and life-sciences names such as IQVIA, Danaher, and Thermo Fisher among the sector's other leaders, indicating that the rally is the result of renewed enthusiasm for the industry instead of a single-stock event.

Messenger RNA drug developers Arcturus Therapeutics and Moderna traded lower on Friday after BioNTech halted a mid-stage trial for its mRNA-based cancer vaccine BNT122, developed with Roche, due to efficacy concerns. Arcturus lost more than 7%, while Moderna fell for a third consecutive session, weighed down by the trial setback and a new $2.6B convertible note offering. Last week, Moderna shares had climbed to a post-pandemic peak after a late-stage trial win for its own mRNA cancer shot, Intismeran, developed with Merck. BioNTech's BNT122-01 study enrolled patients with surgically removed colorectal cancers, whereas Moderna's Phase 3 INTerpath-001 trial targeted resected melanoma. BioNTech said it discontinued the trial after a data safety monitoring board noted a numerical imbalance in overall survival between treatment arms, determining the trial was unlikely to reach its efficacy outcome. Scotiabank analyst Louise Chen argued the decision bodes well for Merck, while BMO Capital Markets analyst Evan David Seigerman called it a clear setback but noted the negative read-through is not necessarily one-to-one across indications.

Tempus AI, Inc. (NASDAQ:TEM) rallied after Moderna and Merck reported that their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda, with detailed data still pending. The read-through came from Personalis, which has supported the V940 program since its inception and which Tempus agreed in July to acquire at a $1.5 billion enterprise value, net of Tempus's existing stake. The clinical win validates Personalis's sequencing capabilities, but it does not establish the economics of either its ImmunoID NeXT platform or the NeXT Personal MRD test, the latter being the central strategic target of the acquisition. Tempus reported 9,000 total MRD tests in the second quarter, up from 6,500 sequentially, while Personalis delivered finalized quarterly revenue of $22.357 million and 10,384 clinical tests, with volume rising 33% sequentially. The deal, structured entirely in Tempus stock at $16.25 per share with an option to pay up to 50% in cash, remains demanding relative to Personalis's scale, as Personalis recorded a second-quarter net loss of $31.683 million, and the $1.5 billion valuation still needs independent economic proof through MRD adoption, reimbursement, and biopharma demand.

Merck shares reached a fresh 52-week high yesterday, driven by investor confidence in its long-term growth prospects, pipeline progress, regulatory approvals, and recent acquisitions. The rally follows positive top-line data from the phase III INTerpath-001 study, which evaluated Merck and Moderna's personalized cancer therapy combo in high-risk melanoma patients, meeting its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival. Merck's biggest revenue driver, Keytruda, recorded sales of $16.40 billion in the first half of 2026, up nearly 4.2% year over year, with its subcutaneous formulation Keytruda Qlex contributing $590 million. The company's newer products, including Winrevair, Capvaxive, and Welireg, have shown encouraging growth, and recent approvals include the RSV antibody Enflonsia, Idvynso, and Lipfendra. Merck also strengthened its pipeline through the 2025 acquisition of Verona Pharma and the 2026 buyouts of Cidara Therapeutics and Terns Pharmaceuticals, and it expects more than $70 billion of potential non-risk-adjusted commercial opportunity from its current pipeline by the mid-2030s, more than double the peak consensus sales estimate for Keytruda of $35 billion in 2028. Year to date, Merck shares have rallied 50.9%, outperforming the industry's 19.9% rise, though the stock trades at a premium with a forward P/E of 21.33 versus the industry's 19.44.

Overnight in the US market, mRNA vaccine maker Moderna saw its share price jump 14.36 percent, lifting vaccine sectors in both A-shares and Hong Kong stocks. On August 26, A-share CanSino Biologics hit the daily limit up, Wantai Biological Pharmacy also hit the daily limit up, while Zhifei Biological Products and Walvax Biotechnology rose more than 6 percent. In Hong Kong, CanSino Biologics surged more than 20 percent. Earlier, Moderna and Merck jointly announced that their personalised mRNA cancer vaccine met the primary endpoint in a Phase III clinical trial, making it the world's first personalised neoantigen therapy to deliver a positive result. Chinese companies such as CanSino Biologics have already announced plans to develop personalised mRNA tumour vaccines. However, the vaccine currently targets only melanoma, and its production cost is relatively high, so it is still some distance from being widely available to ordinary patients. Industry insiders estimate that its cost is lower than cell therapy but higher than ordinary antibody drugs, and China's mRNA cancer vaccine development remains in the early clinical stage.

Merck & Co., Inc. jumped 12.6% to a record $152.20 on August 19 after a pivotal melanoma trial validated intismeran autogene, the individualized mRNA cancer therapy developed with Moderna. In the 1,137-patient Phase 3 INTerpath-001 study, intismeran plus Keytruda produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone, with no new safety concerns. The result strengthens the case that Keytruda, which generated $31.68 billion in 2025 sales, can remain commercially relevant after its primary compound patent expires in December 2028. However, Merck and Moderna share development costs and profits equally, and the companies have not disclosed Phase 3 effect sizes or overall-survival data, leaving approval, pricing, and reimbursement unresolved.

Merck and Moderna announced positive topline Phase 3 results for their individualized cancer vaccine intismeran autogene in resected melanoma, beating Keytruda alone on recurrence-free survival, though no specific efficacy numbers have been released yet. The news lifted several biotech names, with BioNTech surging 21.6% on read-across excitement and Illumina rising 15.6% to $223.22 because its NovaSeq X sequencers are required for every individualized neoantigen dose manufactured. Pacific Biosciences gained 5.8% to $1.28, Repligen traded at $181.62 after reporting second-quarter revenue of $204 million with 13% organic growth, and Danaher saw mid-teens bioprocessing order growth in the second quarter. Leerink Partners analyst Daina Graybosch called the market reaction overly optimistic but still raised her 2032 intismeran forecast to $1.4 billion, while Morningstar projects $16.8 billion by 2035.

Moderna and Merck announced that their individualized mRNA neoantigen therapy paired with Keytruda hit its primary endpoint in the Phase 3 INTerpath-001 melanoma trial, triggering a nearly 177% rally in Moderna, a gain of over 12% for Merck, and a jump of more than 4% in the SPDR S&P Biotech ETF to its highest level since February 2021. The trial win lifted gene-editing and AI drug discovery names broadly, with Prime Medicine, Intellia, CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics rallying alongside the sector, and the iShares Genomics Immunology and Healthcare ETF jumping 13.53% in a single session on 2.8 times average volume. Analysts have turned more constructive on biotech ETFs, citing valuation, technical momentum, and M&A potential, with Bank of America's Research Investment Committee noting biotech has generated returns of roughly 10% or more since June and is being flagged as a diversification play away from crowded technology positioning. Potential targets for M&A include Revolution Medicines, IDEAYA Biosciences, Arcus Biosciences, and Iovance Biotherapeutics, while risks include macro shocks and the structural volatility of small-cap clinical-stage names.

Moderna and Merck announced that their personalized mRNA cancer therapy intismeran autogene, combined with Keytruda, met its primary endpoint of recurrence-free survival in a late-stage melanoma study. The INTerpath-001 trial also met the secondary goal of distant metastasis-free survival in patients with high-risk Stage IIB-IV melanoma after surgery. The companies are testing intismeran in nine additional phase II and III studies across lung, bladder, and kidney cancers. Moderna sees the result as validation of its mRNA platform beyond infectious-disease vaccines, though it still faces competition from BioNTech and others, and its stock trades at a premium with a Zacks Rank of 3, or Hold.

Merck and Moderna announced that their Phase 3 INTerpath-001 trial of the personalized mRNA cancer vaccine Intismeran, combined with Keytruda, met its primary endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma. The trial enrolled 1,137 patients, and the companies called it the first positive Phase 3 result for an individualized mRNA cancer therapy. Merck shares jumped about 12.5%, adding roughly $43 billion in market value, as investors saw the result as validation of the technology and a potential answer to the looming patent cliff for Keytruda in 2028. Goldman Sachs raised its price target to $160 from $140, while UBS, Bank of America, and JPMorgan also lifted targets, though RBC downgraded the stock to Sector Perform. The companies plan to present full data and file with regulators, with additional readouts in kidney, bladder, and lung cancers expected in 2026 and 2027.

GeoVax Labs highlighted positive Phase 3 results from Moderna and Merck's intismeran autogene plus KEYTRUDA combination in resected high-risk melanoma, calling it clinical validation for its planned Gedeptin plus KEYTRUDA study. The INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, showing statistically significant and clinically meaningful improvements over KEYTRUDA alone. GeoVax believes the success reinforces the broader paradigm of combining checkpoint inhibition with therapies that generate or enhance anti-tumor immune responses, directly supporting its Gedeptin development strategy. Gedeptin uses a gene-directed enzyme prodrug therapy to destroy tumors locally and prime the tumor microenvironment, and published preclinical research showed enhanced anti-tumor immune responses when combined with anti-PD-1 therapy. GeoVax is preparing the next phase of Gedeptin clinical development in combination with KEYTRUDA for head and neck squamous cell carcinoma.

In the US market, the flow of funds from AI-related stocks to pharmaceutical stocks has strengthened, and shares of biopharmaceutical maker Moderna, which announced positive clinical trial results for a skin cancer vaccine, surged 2.3 times compared with the previous weekend. Merck, a major pharmaceutical company co-developing the cancer vaccine with Moderna, also rose 12.3 percent, with pharmaceutical stocks taking over the market's lead from AI stocks. Last week, stock prices fell sharply, led by AI stocks, due to concerns over rising global long-term interest rates and massive corporate bond issuance by AI companies. This week, Nvidia's earnings are scheduled for the 27th, and Federal Reserve Chair Warsh's speech at the Jackson Hole conference is scheduled for the 28th. Nvidia is expected to post rapid growth in both revenue and profit for the May-July 2026 quarter, nearly doubling year over year, but its stock price has continued to fall after earnings releases due to concerns over circular transactions involving massive loans to customers.

Merck disclosed an equity stake in Evaxion A/S tied to an AI-powered vaccine program centered on candidate EVX-B3. The company in-licensed EVX-B3, an AI-guided vaccine candidate, as part of its push into AI-driven vaccine discovery. The move extends Merck's use of artificial intelligence beyond its existing focus on traditional pharmaceuticals and mRNA oncology research. Merck is already working with Moderna on individualized mRNA cancer therapy intismeran in combination with KEYTRUDA, where the Phase 3 INTerpath-001 trial met its primary and key secondary endpoints in high-risk melanoma. Adding Evaxion's AI-guided EVX-B3 program extends that effort into AI-supported vaccine design rather than relying only on traditional discovery approaches.

Moderna nearly doubled in value on Wednesday after its messenger-RNA-based cancer vaccine, developed with Merck, succeeded in a late-stage trial for melanoma patients. The Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival versus Merck's Keytruda alone. William Blair upgraded Moderna to Outperform from Market Perform, and CEO Stephane Bancel said the personalized shot could be approved as early as 2027. Separately, Aurora Cannabis confirmed Curaleaf Holdings has commenced an unsolicited takeover bid for all outstanding shares at implied consideration of $4 per share, comprising 0.3463 Curaleaf shares and $0.75 in cash. Eli Lilly also inked a collaboration with privately held Amplitude Therapeutics to develop trans-amplifying RNA vaccine candidates for infectious diseases, while Twist Bioscience jumped more than 15% after Anthropic selected it as an independent evaluator for AI-designed protein binders.